Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2024-04-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
关于第一期员工持股计划实施进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of the company's first employee stock ownership plan implementation. It details the number of employees participating, the amount of funds raised, the allocation of shares among directors, supervisors, senior management, and other employees, as well as stock purchases made in the secondary market. The document is a formal disclosure of the status and progress of an employee share plan, which is a capital-related update rather than a full financial report or management discussion. It does not contain comprehensive financial statements or quarterly/yearly results, nor is it a regulatory certification or voting result. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (1594 characters), but it contains substantive information about capital structure changes related to employee stock ownership, not just a report publication announcement or a regulatory filing. Confidence is high due to clear content and context.
2024-04-29 Chinese
2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年第一季度报告' which translates to '2024 First Quarter Report'. It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2024. The report explicitly states it is unaudited and covers a period shorter than a full fiscal year (quarterly). It includes comprehensive financial statements and analysis, which fits the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or certification. Therefore, the appropriate classification is 'IR'. Q1 2024
2024-04-28 Chinese
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2023 年年度报告摘要" which translates to "2023 Annual Report Summary". It contains detailed information about the company's business, industry background, risk factors, financial conditions, and future plans. The length is substantial (15,000 characters), indicating it is a full report or a significant excerpt of the annual report, not just an announcement or a brief summary. The content includes management discussion and analysis, industry overview, business model, and risk disclosures, which are typical components of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement of a report or a certification letter. Therefore, the document should be classified as an Annual Report (10-K). FY 2023
2024-04-24 Chinese
海通证券股份有限公司关于和元生物技术（上海）股份有限公司继续使用暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Haitong Securities regarding Heyuan Biotechnology's continued use of temporarily idle raised funds for cash management. It references regulatory guidelines on the management and use of raised funds, details on the raised funds, investment projects, board approvals, risk controls, and supervisory opinions. The document is not a full financial report but a regulatory compliance and verification statement related to the use of raised funds. It does not contain financial statements or earnings data, nor is it a brief announcement or a presentation. It fits best as a Regulatory Filing (RNS) because it is a compliance-related document that does not fit into other specific categories like Annual Report, Interim Report, or Capital Update. The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not RPA. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-04-24 Chinese
上海市金茂律师事务所关于和元生物技术（上海）股份有限公司2021年股票期权激励计划第二个行权期行权条件成就及注销部分股票期权之法律意见书
Regulatory Filings
2024-04-24 Chinese
关于续聘2024年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the audit firm Tianjian Accounting Firm for the fiscal year 2024. It details the firm's background, qualifications, independence, and the approval process by the board and audit committee. The document does not contain any financial statements or audit results itself, but rather informs shareholders about the intention to renew the audit engagement subject to shareholder approval. The document length is about 3,035 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit firm appointment and audit-related information, but is not a full annual report or audit report itself. It is not a Regulatory Filing (RNS) because it is a substantive announcement about audit firm reappointment, not a certification or miscellaneous filing. It is not a Report Publication Announcement (RPA) because it does not mention publication or availability of a report. Hence, the classification is AR with high confidence. FY 2024
2024-04-24 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.